December 23, 2025 · Form 4 insider transaction
PERCEPTIVE ADVISORS LLC bought 329,756 shares of Athira Pharma, Inc. at $6.35 per share, a transaction worth $2.09M. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 0 days after the transaction.
Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant.; The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor.; Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.